Response rate of fibrosarcoma cells to cytotoxic drugs on the expression level correlates to the therapeutic response rate of fibrosarcomas and is mediated by regulation of apoptotic pathways

BackgroundBecause of the high resistance rate of fibrosarcomas against cytotoxic agents clinical chemotherapy of these tumors is not established. A better understanding of the diverse modes of tumor cell death following cytotoxic therapies will provide a molecular basis for new chemotherapeutic strategies. In this study we elucidated the response of a fibrosarcoma cell line to clinically used cytostatic agents on the level of gene expression.MethodsHT1080 fibrosarcoma cells were exposed to the chemotherapeutic agents doxorubicin, actinomycin D or vincristine. Total RNA was isolated and the gene expression patterns were analyzed by microarray analysis. Expression levels for 46 selected candidate genes were validated by quantitative real-time PCR.ResultsThe analysis of the microarray data resulted in 3.309 (actinomycin D), 1.019 (doxorubicin) and 134 (vincristine) probesets that showed significant expression changes. For the RNA synthesis blocker actinomycin D, 99.4% of all differentially expressed probesets were under-represented. In comparison, probesets down-regulated by doxorubicin comprised only 37.4% of all genes effected by this agent. Closer analysis of the differentially regulated genes revealed that doxorubicin induced cell death of HT1080 fibrosarcoma cells mainly by regulating the abundance of factors mediating the mitochondrial (intrinsic) apoptosis pathway. Furthermore doxorubicin influences other pathways and crosstalk to other pathways (including to the death receptor pathway) at multiple levels. We found increased levels of cytochrome c, APAF-1 and members of the STAT-family (STAT1, STAT3), while Bcl-2 expression was decreased. Caspase-1, -3, -6, -8, and -9 were increased indicating that these proteases are key factors in the execution of doxorubicin mediated apoptosis.ConclusionThis study demonstrates that chemotherapy regulates the expression of apoptosis-related factors in fibrosarcoma cells. The number and the specific pattern of the genes depend on the used cytotoxic drug. The response rates on the gene expression level, i.e. the number of genes regulated by the drugs actinomycin D, doxorubicin and vincristine, correlate to the clinical effectiveness of the drugs. Doxorubicin seems to exert its cytotoxic mechanism by regulating genes, which are involved in several different apoptosis regulating pathways. The exact knowledge of the genes affected by the drugs will help to understand the diverse modes of soft tissue sarcoma cell death in response to cytotoxic therapies.

[1]  D. Vaux,et al.  Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die , 2004, The Journal of cell biology.

[2]  P. Anderson,et al.  Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules , 2000, Cell Death and Differentiation.

[3]  T. Triche,et al.  cDNA microarray analysis of global gene expression in sarcomas , 2002, Current opinion in oncology.

[4]  M. Lanotte,et al.  Apoptosome-independent Pathway for Apoptosis , 2003, Journal of Biological Chemistry.

[5]  L. Zelek.  [Chemotherapy in soft tissue sarcomas]. , 2006, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[6]  Huey-Jen Lin,et al.  Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas Stimulation* , 2004, Journal of Biological Chemistry.

[7]  A. Thorburn,et al.  Direct Binding of Fas-associated Death Domain (FADD) to the Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor DR5 Is Regulated by the Death Effector Domain of FADD* , 2004, Journal of Biological Chemistry.

[8]  P. Krammer,et al.  Death receptors in chemotherapy and cancer , 2004, Oncogene.

[9]  C. Borner,et al.  Apoptosis without caspases: an inefficient molecular guillotine? , 1999, Cell Death and Differentiation.

[10]  K. Phillips,et al.  Chemotherapy for soft tissue sarcomas. Indications and advances. , 1997, Acta orthopaedica Scandinavica. Supplementum.

[11]  S. Lowe,et al.  Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. , 1999, Science.

[12]  K. Hunt,et al.  Experimental approaches to treatment of soft tissue sarcoma. , 2003, Surgical oncology clinics of North America.

[13]  J. Pablos.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001 .

[14]  M. Los,et al.  Caspases and cancer: mechanisms of inactivation and new treatment modalities. , 2004, Experimental oncology.

[15]  A. Skubitz,et al.  Differential gene expression in leiomyosarcoma , 2003, Cancer.

[16]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[17]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[18]  J. Colicelli,et al.  Human RAS Superfamily Proteins and Related GTPases , 2004, Science's STKE.

[19]  R. Bast,et al.  Expression of BAG-1 and BcL-2 Proteins Before and After Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer , 2004, Cancer investigation.

[20]  P. Singal,et al.  Oxidative Stress and Apoptosis in Heart Dysfunction , 2002, Herz.

[21]  H. Coley.  Drug resistance studies using fresh human ovarian carcinoma and soft tissue sarcoma samples. , 1997, The Keio journal of medicine.

[22]  O. Ogawa,et al.  TRAIL and chemotherapeutic drugs in cancer therapy. , 2004, Vitamins and hormones.

[23]  Trond Stokke,et al.  Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. , 2004, International journal of oncology.

[24]  R. Sylvester,et al.  Mitomycin C (MCC) in advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. , 1985, European journal of cancer & clinical oncology.

[25]  R. Benjamin,et al.  Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. , 1980, Cancer treatment reports.

[26]  M. Soengas,et al.  Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation , 2003, British Journal of Cancer.

[27]  N. Nissen,et al.  Anthracycline resistance. , 1989, Acta oncologica.

[28]  T. Yamamoto,et al.  Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. , 1998, The Journal of endocrinology.

[29]  L. Pusztai.  Perspectives and challenges of clinical pharmacogenomics in cancer. , 2004, Pharmacogenomics.

[30]  A. Rebbaa,et al.  Caspase inhibition switches doxorubicin-induced apoptosis to senescence , 2003, Oncogene.

[31]  Emad S. Alnemri,et al.  Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner , 1999, The Journal of cell biology.

[32]  G. Kroemer,et al.  Chemotherapy: targeting the mitochondrial cell death pathway , 2002, Oncogene.

[33]  F. Ruymann,et al.  Progress in the Diagnosis and Treatment of Rhabdomyosarcoma and Related Soft Tissue Sarcomas , 2000, Cancer investigation.

[34]  G. Demetri,et al.  Management of soft-tissue sarcomas: an overview and update. , 2000, The Lancet. Oncology.

[35]  F. Domann,et al.  The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. , 2004, Neoplasia.

[36]  P. Picci,et al.  Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  M. Berretta,et al.  Ifosfamide in the Adjuvant Therapy of Soft Tissue Sarcomas , 2003, Oncology.

[38]  M. Kuo,et al.  Interleukin‐6 is responsible for drug resistance and anti‐apoptotic effects in prostatic cancer cells , 2004, The Prostate.

[39]  K. Schulze-Osthoff,et al.  Many cuts to ruin: a comprehensive update of caspase substrates , 2003, Cell Death and Differentiation.

[40]  D. Vaux,et al.  Alterations in the apoptotic machinery and their potential role in anticancer drug resistance , 2003, Oncogene.

[41]  Y. Tsujimoto.  Cell death: regulation by the Bcl‐2 protein family , 2006 .

[42]  D. Bredesen,et al.  An alternative, nonapoptotic form of programmed cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[43]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[44]  Y Taya,et al.  p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. , 2001, Molecular cell.

[45]  E. Slee,et al.  Serial killers: ordering caspase activation events in apoptosis , 1999, Cell Death and Differentiation.

[46]  D. Trump,et al.  RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells , 2004, The Prostate.

[47]  A. Raz,et al.  Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf‐1 and Caspase‐9 apoptosome expression , 2003, International journal of cancer.

[48]  J. Yuan,et al.  Molecular control of life and death. , 1995, Current opinion in cell biology.

[49]  D. Botstein,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[50]  S H Kaufmann,et al.  Programmed cell death: alive and well in the new millennium. , 2001, Trends in cell biology.

[51]  A. Rebbaa,et al.  Factors Secreted by Human Neuroblastoma Mediate Doxorubicin Resistance by Activating STAT3 and Inhibiting Apoptosis , 2001, Molecular medicine.

[52]  E. van den Berg,et al.  Multidrug resistance proteins in primary and metastatic soft-tissue sarcomas: down-regulation of P-glycoprotein during metastatic progression. , 2004, Anticancer research.

[53]  G. Ciliberto,et al.  Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL* , 2001, The Journal of Biological Chemistry.

[54]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[55]  J. Gueulette,et al.  Caspase 8-mediated cleavage of the pro-apoptotic BCL-2 family member BID in p53-dependent apoptosis. , 2003, Biochemical and biophysical research communications.

[56]  I. Herr,et al.  Cellular stress response and apoptosis in cancer therapy. , 2001, Blood.

[57]  D. Banerjee,et al.  Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  Henning Walczak,et al.  The interplay between the Bcl-2 family and death receptor-mediated apoptosis. , 2004, Biochimica et biophysica acta.

[59]  Alcino J. Silva,et al.  The RAS Effector RIN1 Modulates the Formation of Aversive Memories , 2003, The Journal of Neuroscience.

[60]  Marcel Leist,et al.  Four deaths and a funeral: from caspases to alternative mechanisms , 2001, Nature Reviews Molecular Cell Biology.

[61]  N. Mitsiades,et al.  The role of apoptosis-inducing receptors of the tumor necrosis factor family in thyroid cancer. , 2003, The Journal of endocrinology.

[62]  K. Yeh,et al.  Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death , 2004, Oncogene.

[63]  K. Debatin,et al.  Apoptosis pathways in cancer and cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[64]  V. L. Johnson,et al.  Effector caspases are dispensable for the early nuclear morphological changes during chemical-induced apoptosis. , 2000, Journal of cell science.

[65]  A. Thorburn,et al.  The C-terminal Tails of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) and Fas Receptors Have Opposing Functions in Fas-associated Death Domain (FADD) Recruitment and Can Regulate Agonist-specific Mechanisms of Receptor Activation* , 2004, Journal of Biological Chemistry.

[66]  Anastasis Stephanou,et al.  STAT‐1: a novel regulator of apoptosis , 2003, International journal of experimental pathology.

[67]  G. Salvesen,et al.  Caspase activation: the induced-proximity model. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Martinou,et al.  Mitochondria: regulating the inevitable. , 2002, Biochimie.

[69]  D. Crowe,et al.  A common pathway for chemotherapy-induced apoptosis in human squamous cell carcinoma lines distinct from that of receptor-mediated cell death. , 2003, Anticancer research.

[70]  T. McDonnell,et al.  Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma , 2004, Oncogene.

[71]  M Bonetti,et al.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  V. Bramwell,et al.  Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. , 2003, The Cochrane database of systematic reviews.

[73]  V. Sondak,et al.  A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin , 2004, British Journal of Cancer.

[74]  Dihua Yu,et al.  Wild type p53 sensitizes soft tissue sarcoma cells to doxorubicin by down‐regulating multidrug resistance‐1 expression , 2001, Cancer.

[75]  W. Kraybill,et al.  Review: Management of soft tissue sarcomas of the extremity in adults , 1996 .

[76]  J. Joseph,et al.  Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis. , 2004, Methods in enzymology.

[77]  A. Rebbaa,et al.  Senescence-initiated Reversal of Drug Resistance , 2004, Cancer Research.

[78]  A. Wyllie,et al.  T Cell Death and Transforming Growth Factor β1 , 2001, The Journal of experimental medicine.

[79]  Takahide Ota,et al.  LyGDI functions in cancer metastasis by anchoring Rho proteins to the cell membrane , 2004, Molecular carcinogenesis.

[80]  M. Bittner,et al.  Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. , 2000, Cancer research.

[81]  P. Reichardt.  High-dose chemotherapy in adult soft tissue sarcoma. , 2002, Critical reviews in oncology/hematology.